Reporter brief
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol paper describing a planned study; no efficacy results have yet been reported
- The effect sizes and clinical significance of any benefit or harm from these interventions remain unknown until outcome data are published
- Whether benefits in liver-specific outcomes translate to improvements in mortality, transplantation rates, or quality of life has not been established
Study design and sample
Rct; Human.
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at increased risk of developing major adverse liver outcomes (MALO), identified by non-invasive tests (NITs).
- Design
- Rct
- Sample
- 4,500
- Journal
- Eli Lilly and Company
- Published
- Sep 22, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Eli Lilly and Company
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.